Controlled medication - Anti-IgE

Question 1

Omalizumab (Xolair®)
Dosage form

Answer 1

150mg/1mL prefilled syringe
75mg/0.5mL prefilled syringe
150 mg/1.2 mL after reconstitution with 1.4 mL sterile water for injection

Question 2

Omalizumab (Xolair®)’
Dosing

Answer 2

Dosing in 5-11-year-olds
- (> 6 yo) 150-375 mg subcutaneously Q2-4 weeks, depending on body weight and pretreatment serum IgE levels
Adult dosing
- 150-375 mg subcutaneously Q2-4 * weeks, depending on body
weight and pretreatment serum
IgE levels

Question 3

Adverse effects

Answer 3

AE: headache, injection site reactions, arthralgias, thrombocytopenia, pharyngitis, sinusitis, upper respiratory tract infections
Boxed warning: anaphylaxis
* Do not give more than 150 mg per injection site
* Monitor for anaphylaxis before and after injection
* FDA approved for moderate to severe persistent
asthma in patients with a positive skin test or reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with ICS